Hisense HD60 Ultrasound Is Installation at Vaal Radiology, South Africa

Hisense, a manufacturer and provider of high-performance electronics and medical devices, has recently installed the Hisense Ultrasound HD60 at Vaal Radiology, a medical imaging center in Vereeninging, South Africa. This color Doppler ultrasound system is ideal for various ultrasound applications including general abdominal, vascular, and small parts.

“Hisense has established itself as a reliable brand globally through its R&D and clinical evaluations. The installation of the HD60 Ultrasound at Vaal Radiology is testament to the growing demand for Hisense’s cutting-edge, high-resolution, ultrasound devices in South Africa,” said Ronele Prince of Hisense.

Designed to provide clinicians with clearer, higher resolution imaging, the HD60 ultrasound system boasts advanced imaging algorithms and a GPU parallel architecture, which allow for faster processing of acoustic data and more precise imaging. Equipped with AI technology and comprehensive application packages, this system is the ideal tool for radiology ultrasound applications such as the abdomen, small parts, vascular, and more.

The Hisense Ultrasound HD60 is used in over 30 hospitals in China, facilitating over 50,000 diagnoses. In January 2022, Hisense received the SAHPRA license for the device in South Africa. In April 2022, Hisense secured its first order for a batch of Ultrasound HD60s in South Africa, marking a major milestone towards becoming a key player in the medical equipment sector.

Hisense has international certifications such as European Union CE MDR and American FDA, which have given the company access to the global medical device market. The company, through its ultrasound and medical display products, has a presence in many countries across the globe including the United Arab Emirates, Iraq, Indonesia, Thailand, Germany, Zimbabwe, Ghana as well as South Africa positioning it for continued growth in and beyond these regions.

Hisense is dedicated to delivering excellent products and services to its customers while fulfilling its healthcare mission. The company’s drive to innovate and enhance its offerings is unwavering. Through its state-of-the-art technology and continuous R&D, Hisense is proof of the scientific and technological strength of Chinese brands to users worldwide.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy